Mar 2017 $3 M Private placement after listing $2 to $10 million 2
Coronado Biosciences Inc.: Private sale, Mar 2017 × Investors in this round 2 investors had bought by the notice of Apr 19, 2017: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $325,400
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice George K. Avgerinos · Executive Officer Lindsay A. Rosenwald · Executive Officer, Director Lucy S. Lu · Executive Officer Dov K. Klein · Director Eric K. Rowinsky · Director J. Jay Lobell · Director Jimmie S. Harvey, Jr. · Director Malcolm S. Hoenlein · Director Michael S. Weiss · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition to the cash commission above, Issuer also issued warrants to purchase 87,946 shares of the Company's common stock at an exercise price of $3.70 per share.”On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by Lindsay A. Rosenwald, MD, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 19, 2017. Read the notice at the SEC .
debt, options SEC May 2011 $26 M No. 5 $10 to $50 million 344
Coronado Biosciences Inc.: Raise no. 5, May 2011 × Investors in this round 344 investors had bought by the notice of Jul 5, 2011: 344 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $26 M of $29 M offered; $3 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,580,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bobby W. Sandage · Executive Officer, Director Dale W. Ritter · Executive Officer Glenn L. Cooper · Executive Officer, Director David J. Barrett · Director Eric K. Rowinsky · Director J. Jay Lobell · Director Jimmie Jay Harvey · Director Lindsay A. Rosenwald · Director Michael W. Rogers · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round National Securities Corporation (CRD 7569) · New York, New York Sold in all US states Remarks in the notice On the amounts: “Includes aggregate amount receivable upon exercise of a warrant to purchase the Issuer's Common Stock and warrants to purchase the Issuer's Series C Preferred Stock (assuming no net exercise, where applicable). The warrants have not yet been exercised.”Signed by Dale Ritter, Sr. VP. , Finance. Source: SEC Form D and 1 amendment, newest notice filed Jul 5, 2011. Read the notice at the SEC .
equity, options SEC Jan 2011 $14 M No. 4 $10 to $50 million 1
Coronado Biosciences Inc.: Raise no. 4, Jan 2011 × Investors in this round 1 investor had bought by the notice of Jan 19, 2011: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elizabeth Moore · Executive Officer Gary L. Gemignani · Executive Officer Glenn L. Cooper · Executive Officer, Director Peggy M. Wentworth · Executive Officer Timothy M. Hillman · Executive Officer Timothy M. Hofer · Executive Officer Eric K. Rowinsky · Director J. Jay Lobell · Director Jimmie M. Harvey · Director Lindsay A. Rosenwald · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents value of certain shares of the Issuer's preferred stock which were exchanged as consideration for the acquisition of certain assets.”Signed by Gary Gemignani, Executive VP, COO & CFO. Source: SEC Form D, newest notice filed Jan 19, 2011. Read the notice at the SEC .
equity SEC May 2010 $4 M No. 3 $2 to $10 million 41
Coronado Biosciences Inc.: Raise no. 3, May 2010 × Investors in this round 41 investors had bought by the notice of Jun 8, 2010: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $28 M offered; $24 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,499,999
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elizabeth J. Moore · Executive Officer Gary L. Gemignani · Executive Officer Linda J. Rogers · Executive Officer Peggy M. Wentworth · Executive Officer Raymond J. Tesi · Executive Officer, Director Timothy M. Hofer · Executive Officer Glenn L. Cooper · Director J. Jay Lobell · Director Jimmie M. Harvey · Director Lindsay A. Rosenwald · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paramount BioCapital, Inc. (CRD 29795) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “Estimate represents maximum sales commission payable.”On the amounts: “Includes amounts receivable upon exercise of certain warrants. The warrants have not yet been exercised.”Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed Jun 8, 2010. Read the notice at the SEC .
equity, options SEC Apr 2010 $7 M No. 2 $2 to $10 million 25
Coronado Biosciences Inc.: Raise no. 2, Apr 2010 × Investors in this round 25 investors had bought by the notice of May 7, 2010: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $8 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elizabeth J. Moore · Executive Officer Linda J. Rogers · Executive Officer Peggy M. Wentworth · Executive Officer Raymond J. Tesi · Executive Officer, Director Stephen M. Pilatzke · Executive Officer Timothy M. Hofer · Executive Officer Glenn L. Cooper · Director J. Jay Lobell · Director Jimmie M. Harvey · Director Lindsay A. Rosenwald · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paramount BioCapital, Inc. (CRD 29795) · New York, New York Sold in all US states Remarks in the notice On fees: “Upon each closing, the Issuer will pay Paramount commissions equal to 10% of the gross proceeds received at such closing. The commissions paid above were not applied to the purchase of securities by one investor.”Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed May 7, 2010. Read the notice at the SEC .
equity, options SEC Jul 2009 $1 M No. 1 Under $2 million 16
Coronado Biosciences Inc.: Raise no. 1, Jul 2009 × Investors in this round 16 investors had bought by the notice of Aug 4, 2009: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $4 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Promissory Notes convertible into shares of Preferred Stock, Warrant to Purchase Common Stock and Common Stock issuable upon exercise of the Warrant.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $85,050
Finders' fees none
Paid to its own people $200,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elizabeth Moore · Executive Officer Linda Rogers · Executive Officer Peggy Wentworth · Executive Officer Raymond J. Tesi · Executive Officer, Director Stephen Pilatzke · Executive Officer Timothy M. Hofer · Executive Officer Bertrand Liang · Director J. Jay Lobell · Director Jimmie Harvey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paramount BioCapital, Inc. (CRD 29795) · New York, Ny Sold in all US states Remarks in the notice On fees: “Upon each closing, the Issuer will pay Paramount commissions equal to 7% of the gross proceeds received at such closing, up to $245,000. The commissions paid above were not applied to the purchase of securities by one investor.”On the amounts: “Issuer may issue Convertible Promissory Notes in the principal amount of up to $3,500,000 and a Warrant to purchase Common Stock. The offering amount with respect to the Warrant is based on future values and can not be determined at this time.”On the use of proceeds: “Certain proceeds of the offering will be used to pay employee wages owed to the individuals named in Item 3 above, and certain other employees of the Issuer who are related persons.”Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed Aug 4, 2009. Read the notice at the SEC .
debt, options SEC